Dana Holzinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4794307/publications.pdf

Version: 2024-02-01

361413 477307 1,798 29 20 29 citations h-index g-index papers 29 29 29 2947 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. Journal of the National Cancer Institute, 2016, 108, djv403.	6.3	580
2	The role of HPV RNA transcription, immune responseâ€related gene expression and disruptive <i>TP53</i> mutations in diagnostic and prognostic profiling of head and neck cancer. International Journal of Cancer, 2015, 137, 2846-2857.	5.1	169
3	Viral RNA Patterns and High Viral Load Reliably Define Oropharynx Carcinomas with Active HPV16 Involvement. Cancer Research, 2012, 72, 4993-5003.	0.9	152
4	Sensitivity and specificity of antibodies against HPV16 E6 and other early proteins for the detection of HPV16â€driven oropharyngeal squamous cell carcinoma. International Journal of Cancer, 2017, 140, 2748-2757.	5.1	92
5	Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	77
6	From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treatment Reviews, 2016, 42, 24-29.	7.7	71
7	Human papillomavirus 16 <scp>E</scp> 6 antibodies are sensitive for human papillomavirus–driven oropharyngeal cancer and are associated with recurrence. Cancer, 2017, 123, 4382-4390.	4.1	67
8	Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. Journal of Oral Pathology and Medicine, 2011, 40, 629-635.	2.7	65
9	Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: A retrospective multicentre study. European Journal of Cancer, 2017, 74, 73-81.	2.8	59
10	Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients. Oral Oncology, 2018, 78, 137-144.	1.5	58
11	Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. International Journal of Cancer, 2013, 133, 1389-1399.	5.1	55
12	Role of human papillomavirus infection in the etiology of vulvar cancer in Italian women. Infectious Agents and Cancer, 2020, 15, 20.	2.6	50
13	Mucosal alphaâ€papillomaviruses are not associated with esophageal squamous cell carcinomas: Lack of mechanistic evidence from <scp>S</scp> outh <scp>A</scp> frica, <scp>C</scp> hina and <scp>I</scp> ran and from a worldâ€wide metaâ€analysis. International Journal of Cancer, 2016, 139, 85-98.	5.1	36
14	Role of mucosal highâ€risk human papillomavirus types in head and neck cancers in central India. International Journal of Cancer, 2017, 141, 143-151.	5.1	34
15	Low prevalence of HPV-driven head and neck squamous cell carcinoma in North-East Italy. Papillomavirus Research (Amsterdam, Netherlands), 2016, 2, 133-140.	4.5	30
16	Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer. Oral Oncology, 2017, 70, 43-50.	1.5	28
17	Prevalence and Determinants of Oral Human Papillomavirus Infection in 500 Young Adults from Italy. PLoS ONE, 2017, 12, e0170091.	2.5	28
18	Antibodies against human papillomaviruses as diagnostic and prognostic biomarker in patients with neck squamous cell carcinoma from unknown primary tumor. International Journal of Cancer, 2018, 142, 1361-1368.	5.1	25

#	Article	IF	CITATIONS
19	Role of Human Papillomavirus Infection in Head and Neck Cancer in Italy: The HPV-AHEAD Study. Cancers, 2020, 12, 3567.	3.7	23
20	Role of mucosal high-risk human papillomavirus types in head and neck cancers in Romania. PLoS ONE, 2018, 13, e0199663.	2.5	20
21	Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virology Journal, 2013, 10, 334.	3.4	14
22	Low prevalence of human papillomavirus in head and neck squamous cell carcinoma in the northwest region of the Philippines. PLoS ONE, 2017, 12, e0172240.	2.5	14
23	Antibody Responses to Cancer Antigens Identify Patients with a Poor Prognosis among HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Patients. Clinical Cancer Research, 2019, 25, 7405-7412.	7.0	13
24	HPV DNA genotyping, HPV E6*I mRNA detection, and p16INK4a/Ki-67 staining in Belgian head and neck cancer patient specimens, collected within the HPV-AHEAD study. Cancer Epidemiology, 2021, 72, 101925.	1.9	13
25	Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status. International Journal of Cancer, 2019, 145, 3436-3444.	5.1	8
26	HPV16 RNA patterns defined by novel high-throughput RT-qPCR as triage marker in HPV-based cervical cancer precursor screening. Gynecologic Oncology, 2015, 138, 676-682.	1.4	7
27	Detection of HPV16 /18 E6 Oncoproteins in Head and Neck Squamous Cell Carcinoma Using a Protein Immunochromatographic Assay. Laryngoscope, 2021, 131, 1042-1048.	2.0	6
28	Absence of disruptive TP53 mutations in highâ€risk human papillomavirusâ€driven neck squamous cell carcinoma of unknown primary. Head and Neck, 2019, 41, 3833-3841.	2.0	2
29	Prevalence of Transcriptionally Active HPV Infection in Tumor-Free Oropharyngeal Tissue of OPSCC-Patients. Frontiers in Oncology, 2022, 12, 835814.	2.8	2